Tooth whiteners do not cause cancer

November 16, 2006

Ontario, Canada - November 16, 2006 -- Common tooth whitening products, which have been used by millions of people, are found to be safe and do not increase the risk of oral cancer when used as directed. This exhaustive review of the literature, including numerous unpublished clinical studies involving over 4,000 human subjects, appeared in an article by Dr. Ian Monroe entitled, " Use of Hydrogen Peroxide-Based Tooth Whitening Products and it Relationship to Oral Cancer," published in Journal of Esthetic and Restorative Dentistry.

Clinical and laboratory data on tooth whitening products show no evidence for the development of oral cancer or of other effects that could be associated with increased oral cancer risk. Exposures to hydrogen peroxide, generally the effective ingredient in tooth whiteners, are too low and of too short of a duration (30-60 minutes) to cause any oral tissue changes that could enhance risks for oral cancer development. Concentrations of hydrogen peroxide rapidly decline to near undetectable levels usually within 15 to 60 minutes.

Given the likely use of tooth whitening products by smokers, the review also sought to examine any possibility of increased oral cancer development due to combined exposure (i.e., hydrogen peroxide and carcinogenic agents that are present in cigarette smoke). A possible combined-effect, as seen in the increased likelihood of lung cancer development in smokers also exposed to asbestos, was found to be groundless with regards to bleaching and smoking and further illustrates the relative safety of tooth whitening products.
-end-
This article is published in the current issue of Journal of Esthetic and Restorative Dentistry. Media wishing to receive a PDF of this article please contact profession alnews@bos.blackwellpublishing.net

Dr. Ian Monroe is a professor in the Department of Nutritional Sciences and Faculty of Medicine and Associate Director, Program in Food Safety, Nutrition and Regulatory Affairs at the University of Toronto and Executive Vice President and Senior Scientific Consultant CANTOX Health Sciences International. He can be reached for questions at imunro@cantox.com.

About the Journal

The Journal of Esthetic and Restorative Dentistry is the longest standing peer-reviewed journal devoted solely to advancing the knowledge and practice of esthetic dentistry. Its goal is to provide the very latest evidence-based information in the realm of contemporary interdisciplinary esthetic dentistry through high quality clinical papers, sound research reports and educational features. For more information, please visit http://www.blackwell-synergy.com/loi/jerd

Blackwell Publishing is the world's leading society publisher, partnering with 665 academic and professional societies. Blackwell publishes over 800 journals and, to date, has published more than 6,000 books, across a wide range of academic, medical, and professional subjects. Please visit www.blackwellpublishing.com for more information.

Blackwell Publishing Ltd.

Related Oral Cancer Articles from Brightsurf:

Oral cancer pain predicts likelihood of cancer spreading
Oral cancer is more likely to spread in patients experiencing high levels of pain, according to a team of researchers at NYU College of Dentistry that found genetic and cellular clues as to why metastatic oral cancers are so painful.

Pathogens in the mouth induce oral cancer
Pathogens found in tissues that surround the teeth contribute to a highly aggressive type of oral cancer, according to a study published 1st October in the open-access journal PLOS Pathogens by Yvonne Kapila of the University of California, San Francisco, and colleagues.

Adherence to oral diabetes drugs may improve survival in diabetics with colorectal cancer
Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.

Oral apixaban as good as dalteparin for treating cancer-associated clots
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

New study highlights sociodemographic disparities in oral cancer screening rates
Researchers at Brigham and Women's Hospital led a study to examine oral cancer screening rates among those who had been to the dentist within two years, looking at whether sociodemographic factors such as income or race predicted differences in these rates.

Risks of novel oral prostate cancer therapies and pre-existing conditions
Common prostate cancer therapy may increase short-term risk of death in patients with pre-existing cardiovascular conditions.

Oral cancer detection by dentists is significantly on the rise
After examining data gathered over an 11-year period in a first-of-its-kind provincial study, University of Toronto clinician-scientist Marco Magalhaes says that dentists in Ontario are detecting more cases of oral cancer and pre-cancer than ever before -- and it's saving lives.

Discovery of oral cancer biomarkers could save thousands of lives
Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that.

How a common oral bacteria makes colon cancer more deadly
Researchers have determined how a type of bacteria commonly found in the mouth accelerates the growth of colon cancer.

Lymph node ratio may predict who lives and dies from oral cavity cancer
Patients with lymph node ratio greater than 10 percent had about 2.5 times greater risk of cancer recurrence and 2.7 times greater risk of death than patients with LNR below 10 percent.

Read More: Oral Cancer News and Oral Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.